bluebird bio
BLUE
BLUE was delisted on the 30th of May, 2025.
278 hedge funds and large institutions have $3.94B invested in bluebird bio in 2020 Q2 according to their latest regulatory filings, with 71 funds opening new positions, 119 increasing their positions, 52 reducing their positions, and 39 closing their positions.
129% more repeat investments, than reductions
Existing positions increased: 119 | Existing positions reduced: 52
82% more first-time investments, than exits
New positions opened: 71 | Existing positions closed: 39
42% more capital invested
Capital invested by funds: $2.78B → $3.94B (+$1.16B)
33% more funds holding in top 10
Funds holding in top 10: 3 → 4 (+1)
13% more funds holding
Funds holding: 247 → 278 (+31)
0.67% less ownership
Funds ownership: 8.36% → 7.69% (-0.67%)
14% less call options, than puts
Call options by funds: $39.6M | Put options by funds: $46.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$129M |
| 2 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
+$86.6M |
| 3 |
Capital Research Global Investors
Los Angeles,
California
|
+$74.7M |
| 4 |
CCM
Camber Capital Management
Boston,
Massachusetts
|
+$74.2M |
| 5 |
BlackRock
New York
|
+$64.7M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$166M |
| 2 |
Victory Capital Management
San Antonio,
Texas
|
-$112M |
| 3 |
Citadel Advisors
Miami,
Florida
|
-$55.6M |
| 4 |
Adage Capital Partners
Boston,
Massachusetts
|
-$54.2M |
| 5 |
Capital World Investors
Los Angeles,
California
|
-$50.7M |
BLUE Hedge Fund Activity: Q2 2020 in Review
278 of the 4,878 institutional investors tracked by Wall St. Rank reported a position in bluebird bio (BLUE) for Q2 2020, worth a combined $3.94B — up 42% from $2.78B a quarter earlier.
Buyers outnumbered sellers: 71 funds opened new BLUE positions and 39 closed out — a net gain of 32 holders — while 119 added to existing stakes and 52 trimmed.
The largest buyer was Vanguard Group, adding an estimated $129M. The largest seller was Fidelity Investments, cutting an estimated $166M.
- 278 institutional investors held bluebird bio (BLUE) as of Q2 2020, up from 247 in Q1 2020.
- Funds reported $3.94B of bluebird bio stock for Q2 2020, up 42% quarter-over-quarter.
- 71 funds opened new bluebird bio positions in Q2 2020 and 39 closed out, a net change of +32 holders.
- The largest bluebird bio buyer in Q2 2020 was Vanguard Group, an estimated $129M added.
- The largest bluebird bio seller in Q2 2020 was Fidelity Investments, an estimated $166M sold.
Based on aggregated 13F filings for Q2 2020.